JP2021501803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501803A5 JP2021501803A5 JP2020544068A JP2020544068A JP2021501803A5 JP 2021501803 A5 JP2021501803 A5 JP 2021501803A5 JP 2020544068 A JP2020544068 A JP 2020544068A JP 2020544068 A JP2020544068 A JP 2020544068A JP 2021501803 A5 JP2021501803 A5 JP 2021501803A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ophthalmic
- ophthalmic pharmaceutical
- composition according
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 23
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 10
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 10
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 10
- 229930003347 Atropine Natural products 0.000 claims description 8
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 8
- 229960000396 atropine Drugs 0.000 claims description 8
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 230000004379 myopia Effects 0.000 claims description 8
- 208000001491 myopia Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003149 muscarinic antagonist Substances 0.000 claims description 6
- -1 flaboxate Chemical compound 0.000 claims description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 3
- 230000004308 accommodation Effects 0.000 claims description 3
- 210000001747 pupil Anatomy 0.000 claims description 3
- 229960002646 scopolamine Drugs 0.000 claims description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 3
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims description 2
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 claims description 2
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 2
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 claims description 2
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 claims description 2
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 claims description 2
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 claims description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims description 2
- ATKYNAZQGVYHIB-DGKWVBSXSA-N [(1r,5s)-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate Chemical compound C([C@]1(CC[C@@](C2)(N1)[H])[H])C2OC(=O)C(CO)C1=CC=CC=C1 ATKYNAZQGVYHIB-DGKWVBSXSA-N 0.000 claims description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 2
- WOVFJBGKJQEQQD-UHFFFAOYSA-N acridine;hydrobromide Chemical compound [Br-].C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 WOVFJBGKJQEQQD-UHFFFAOYSA-N 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- HGWPFSBHDACWNL-LZYIFBDPSA-N atropine oxyde Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2([O-])C)C(=O)C(CO)C1=CC=CC=C1 HGWPFSBHDACWNL-LZYIFBDPSA-N 0.000 claims description 2
- 229950010917 atropine oxyde Drugs 0.000 claims description 2
- 229960002028 atropine sulfate Drugs 0.000 claims description 2
- 229960001081 benzatropine Drugs 0.000 claims description 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 2
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 claims description 2
- 229960002777 dicycloverine Drugs 0.000 claims description 2
- 229960004993 dimenhydrinate Drugs 0.000 claims description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960000857 homatropine Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 2
- 229960001888 ipratropium Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 229960005096 methylatropine Drugs 0.000 claims description 2
- PIPAJLPNWZMYQA-YVSFHVDLSA-N methylatropine Chemical compound C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c3ccccc3 PIPAJLPNWZMYQA-YVSFHVDLSA-N 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229960005434 oxybutynin Drugs 0.000 claims description 2
- 229960005253 procyclidine Drugs 0.000 claims description 2
- 230000004515 progressive myopia Effects 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- ATKYNAZQGVYHIB-UHFFFAOYSA-N tropaic acid nortropanyl ester Natural products C1C(N2)CCC2CC1OC(=O)C(CO)C1=CC=CC=C1 ATKYNAZQGVYHIB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004791 tropicamide Drugs 0.000 claims description 2
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 239000003732 agents acting on the eye Substances 0.000 claims 1
- 229940100655 ophthalmic gel Drugs 0.000 claims 1
- 229940023490 ophthalmic product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023135274A JP2023179418A (ja) | 2017-11-03 | 2023-08-23 | 近視の進行を制御し且つ／又は減少させるための医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581112P | 2017-11-03 | 2017-11-03 | |
| US62/581,112 | 2017-11-03 | ||
| PCT/AU2018/051187 WO2019084621A1 (en) | 2017-11-03 | 2018-11-02 | Pharmaceutical compositions for controlling and/or reducing the progression of myopia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135274A Division JP2023179418A (ja) | 2017-11-03 | 2023-08-23 | 近視の進行を制御し且つ／又は減少させるための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501803A JP2021501803A (ja) | 2021-01-21 |
| JP2021501803A5 true JP2021501803A5 (enExample) | 2021-12-16 |
Family
ID=66331107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544068A Pending JP2021501803A (ja) | 2017-11-03 | 2018-11-02 | 近視の進行を制御し且つ／又は減少させるための医薬組成物 |
| JP2023135274A Pending JP2023179418A (ja) | 2017-11-03 | 2023-08-23 | 近視の進行を制御し且つ／又は減少させるための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135274A Pending JP2023179418A (ja) | 2017-11-03 | 2023-08-23 | 近視の進行を制御し且つ／又は減少させるための医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200345633A1 (enExample) |
| EP (1) | EP3703691A4 (enExample) |
| JP (2) | JP2021501803A (enExample) |
| KR (1) | KR20200088824A (enExample) |
| CN (3) | CN118384160A (enExample) |
| AU (1) | AU2018359013A1 (enExample) |
| CA (1) | CA3081593A1 (enExample) |
| SG (1) | SG11202004005RA (enExample) |
| TW (1) | TW201932104A (enExample) |
| WO (1) | WO2019084621A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3763280A1 (de) * | 2019-07-11 | 2021-01-13 | Carl Zeiss Vision International GmbH | Bestimmung einer veränderung eines refraktionsfehlers eines auges |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| CN116785286A (zh) * | 2020-10-10 | 2023-09-22 | 远大生命科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
| TW202317132A (zh) * | 2021-06-11 | 2023-05-01 | 澳大利亞商布萊恩荷登視覺協會 | 眼用組合物及/或用於老花眼、瞳孔放大及/或眼部不適管理之方法 |
| CN119139472A (zh) * | 2024-09-26 | 2024-12-17 | 温州医科大学附属眼视光医院 | 腺苷信号阻滞剂在制备治疗弱视和改善视觉可塑性的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG61430B1 (bg) * | 1994-03-23 | 1997-08-29 | Иван ХРИСТОВ | антиастматично лекарствено средство |
| AU2100795A (en) * | 1994-06-06 | 1996-01-04 | Warner-Lambert Company | Non-sedating allergy sinus medication |
| US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
| US6710051B1 (en) * | 1997-01-06 | 2004-03-23 | Klaus Trier Aps | Screening method |
| US20110104083A1 (en) * | 2009-10-30 | 2011-05-05 | Intratus, Inc. | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye |
| WO2012161655A1 (en) * | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| JP5993620B2 (ja) * | 2011-06-01 | 2016-09-14 | ロート製薬株式会社 | 点眼剤 |
| WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
-
2018
- 2018-11-02 CA CA3081593A patent/CA3081593A1/en active Pending
- 2018-11-02 JP JP2020544068A patent/JP2021501803A/ja active Pending
- 2018-11-02 EP EP18872470.2A patent/EP3703691A4/en not_active Withdrawn
- 2018-11-02 CN CN202410507498.4A patent/CN118384160A/zh active Pending
- 2018-11-02 US US16/760,663 patent/US20200345633A1/en not_active Abandoned
- 2018-11-02 KR KR1020207015250A patent/KR20200088824A/ko not_active Ceased
- 2018-11-02 WO PCT/AU2018/051187 patent/WO2019084621A1/en not_active Ceased
- 2018-11-02 CN CN201880085219.2A patent/CN111787920A/zh active Pending
- 2018-11-02 TW TW107139077A patent/TW201932104A/zh unknown
- 2018-11-02 CN CN202410507406.2A patent/CN118403054A/zh active Pending
- 2018-11-02 AU AU2018359013A patent/AU2018359013A1/en not_active Abandoned
- 2018-11-02 SG SG11202004005RA patent/SG11202004005RA/en unknown
-
2023
- 2023-08-23 JP JP2023135274A patent/JP2023179418A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501803A5 (enExample) | ||
| KR102017916B1 (ko) | 노안, 경도 원시 및 불규칙한 난시의 치료를 위한 조성물 및 방법 | |
| EP3031457B1 (en) | Medicament comprising pilocarpine and brimonidine | |
| KR102600484B1 (ko) | 노안의 치료를 위한 조성물 및 방법 | |
| EP3654964B1 (en) | Composition comprising atropine and a miotic agent and its use in the treatment of myopia | |
| ES2708451T3 (es) | Soluciones de bimatoprost y timolol sin conservantes | |
| JP7174175B2 (ja) | 近視の治療、近視の予防および／または近視の進行抑制のための医薬 | |
| JPWO2020087021A5 (enExample) | ||
| JP2017507959A (ja) | 選択された抗コリン作動性両性イオンの使用 | |
| JP2023179418A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| JP2022536460A (ja) | 視力障害を治療するための方法及び製剤 | |
| JP2013534527A (ja) | コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物 | |
| EP3416617B1 (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| CN106456584A (zh) | 用于矫正老视的药理学眼科用组合物和其施用 | |
| Hanna et al. | Ocular penetration of topical chloramphenicol in humans | |
| WO2014127116A1 (en) | Topical ocular analgesic agents | |
| JPWO2022173923A5 (enExample) | ||
| CN103405766B (zh) | 一种贝伐单抗滴眼液及其制备方法 | |
| US20060058345A1 (en) | Use of papaverine-like vasodilator and pharmaceutical composition | |
| RU2793238C2 (ru) | Применение бензтропина с целью остановки прогрессирования аксиальной миопии у человека | |
| HK40039952A (en) | Pharmaceutical compositions for controlling and/or reducing the progression of myopia | |
| Verma et al. | An insight into ocular drug delivery system | |
| Vásquez | Experience in Prevention of Toxic Anterior Segment Syndrome/Endophthalmitis |